Kymera Therapeutics Inc (KYMR) is trading down at $110.85 (-1.58%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on KYMR
One firm's current price target on Kymera Therapeutics Inc: $140 — 26% above the current $111. Each is tracked to its date and scored the same way a member's call is.
- Raymond James $109 → $140 by Oct 2027 Oct 8, 2026 via Investing.com · Raymond James's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Kymera Therapeutics Inc revenue & net income history (FY2019–FY2025)
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $2.93M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Growth (year over year) | — | +1060.0% | +114.0% | −35.7% | +67.8% | −40.1% | −16.7% |
| Gross profit | — | — | — | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating income | −$42.2M | −$46.3M | −$100.5M | −$161.3M | −$165.5M | −$261.6M | −$349.4M |
| Operating margin | −1438.5% | −136.1% | −138.0% | −344.4% | −210.6% | −555.8% | −891.1% |
| Net income | −$41.2M | −$45.6M | −$100.2M | −$154.8M | −$147.0M | −$223.9M | −$311.4M |
| Net margin | −1405.8% | −134.0% | −137.6% | −330.6% | −187.0% | −475.6% | −794.0% |
| EPS (diluted) | −$24.28 | −$3.15 | −$2.09 | −$2.87 | −$2.52 | −$2.98 | −$3.69 |
| Balance sheet | |||||||
| Cash and equivalents | $76.0M | $31.0M | $48.0M | $68.4M | $110.0M | $120.3M | $357.0M |
| Total assets | $116.7M | $487.2M | $605.9M | $603.1M | $575.8M | $978.0M | $1.74B |
| Total liabilities | $82.0M | $203.3M | $146.3M | $113.0M | $180.8M | $142.4M | $163.1M |
| Shareholders' equity | −$74.4M | $283.9M | $459.6M | $490.2M | $395.0M | $835.6M | $1.58B |
| Cash flow | |||||||
| Operating cash flow | $17.9M | $88.1M | −$128.9M | −$153.1M | −$102.8M | −$194.5M | −$232.9M |
| Capital expenditure | $532.0K | $9.10M | $1.60M | $2.84M | $34.5M | $12.8M | $1.45M |
| Free cash flow | $17.4M | $79.0M | −$130.5M | −$155.9M | −$137.3M | −$207.3M | −$234.3M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.74M | $7.39M | $22.1M | $11.5M | $2.76M | — | $34.4M | $65.0M |
| Growth (year over year) | −20.9% | — | +114.8% | −55.3% | −26.1% | — | +55.5% | +466.4% |
| Gross profit | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 |
| Gross margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.0% |
| Operating income | −$72.1M | −$80.8M | −$74.4M | −$84.6M | −$92.5M | — | −$84.2M | −$75.6M |
| Operating margin | −1927.9% | −1092.2% | −336.8% | −736.8% | −3347.4% | — | −244.9% | −116.3% |
| Net income | −$62.5M | −$70.8M | −$65.6M | −$76.6M | −$82.2M | — | −$69.2M | −$61.2M |
| Net margin | −1670.3% | −956.9% | −296.7% | −667.6% | −2973.0% | — | −201.5% | −94.2% |
| EPS (diluted) | −$0.82 | −$0.89 | −$0.82 | −$0.95 | −$0.94 | — | −$0.71 | −$0.62 |
| Balance sheet | ||||||||
| Cash and equivalents | $110.7M | $120.3M | $90.0M | $335.8M | $112.9M | $357.0M | $144.1M | $124.5M |
| Total assets | $1.03B | $978.0M | $918.3M | $1.13B | $1.10B | $1.74B | $1.67B | $1.65B |
| Total liabilities | $141.9M | $142.4M | $132.1M | $159.6M | $155.8M | $163.1M | $129.4M | $136.2M |
| Shareholders' equity | $892.9M | $835.6M | $786.2M | $971.5M | $946.3M | $1.58B | $1.54B | $1.51B |
| Cash flow | ||||||||
| Operating cash flow | −$50.2M | −$61.8M | −$79.2M | −$59.9M | −$27.1M | — | −$88.8M | −$54.1M |
| Capital expenditure | −$189.0K | $936.0K | $467.0K | $695.0K | $181.0K | — | $434.0K | $473.0K |
| Free cash flow | −$50.0M | −$62.7M | −$79.6M | −$60.6M | −$27.3M | — | −$89.3M | −$54.5M |
From Kymera Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Kymera Therapeutics Inc
- Headquarters
- Watertown, Massachusetts From SEC filings, Oct 2026
Recent News (5)
-
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicin…
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation s…
-
Raymond James initiates Kymera Therapeutics stock coverage with outperform rating
Raymond James initiates Kymera Therapeutics stock coverage with outperform rating
-
Kymera Therapeutics at citigroup summit: oral immunology push gains pace
Kymera Therapeutics at citigroup summit: oral immunology push gains pace
-
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International